CellanomeOlmutinibCetuximab-MMAEtumor recurrenceresidual diseaseEGFR inhibitors
…g drug resistant or responsive clones would.Methods We leverage Cellanome’s R3200 platform, a high-throughput, multi-modal platform that …
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: Cellanome ×
Cellanome
This institution is selected. Its supporting articles are shown below.